Background In neonates, the validation of urinary biomarkers to diagnose acute kidney injury is a rapidly evolving field. The neonatal population poses unique challenges when assessing the collection, storage, and processing of urinary samples for biomarker analysis. Given this, establishing optimal and consistent sample processing in this population for meaningful use in ongoing clinical trials is important. Methods Urine from a cohort of 19 hospitalized neonatal intensive care unit patients enrolled in the Preterm Erythropoietin Neuroprotection Trial (Clinical Trial NCT01378273) was collected for biomarker analysis by indirect techniques using Fisher-brand cotton balls placed in the diapers. Fourteen urinary biomarkers were measured using commercially available kits via electrochemiluminescence on multiarray plates and compared between paired samples processed with centrifugation prior to storage versus prior to analysis.
Introduction
The development and discovery of novel urinary biomarkers is an area of active research within nephrology. In neonates, validation of biomarkers in the setting of acute kidney injury (AKI) and chronic kidney disease (CKD) is a rapidly evolving field. Early detection, diagnosis, risk profiling, and prognosis are areas of expanding investigation [1] . A number of large, ongoing clinical studies collect serial urine samples using a variety of methodologies for biomarker collection, storage, and processing, allowing for batch analysis at a later time. Therefore, it is important to establish optimal and consistent processing methods for urine samples in neonates that do not affect biomarker concentration results.
Neonates pose additional challenges compared to other populations when assessing the collection, storage, and processing of urine samples for biomarker analysis. First, the collection of adequate urine volume from infants is often difficult. Indwelling bladder catheters provide a reliable and accurate method of urine collection; however, concerns for catheter-associated urinary tract infections have limited placement to less than 3% of hospitalized infants [2] . Another option for urine sample collection is use of adhesive bags applied to the perineum. These are prone to leakage and/or sample loss, and can cause significant irritation to the skin in preterm infants. Routine clinical and research protocols frequently rely on cotton balls placed in the diapers or special diapers to obtain urine for clinical evaluation of neonates, infants, and young children. Although indirectly collected urine samples produce reliable biochemical results, the processing of these samples is not standardized [3] . A 2010 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop concluded that there are variations in storage and processing in samples in the repository and that protocols are often based on convenience and expert opinion [4] . Several recent studies have sought to evaluate the processing and storage of urinary samples for biomarker analysis in children and adults and found no differences in biomarker concentration based on processing and storage methods; however, these studies evaluated urine samples collected directly from patients via catheterization of the bladder [5, 6] .
In neonates, existing processing protocols require further study. Many study protocols employ processing (centrifugation) prior to storage as investigators worry that residual cotton fibers may affect biomarker results. Selective absorption of urine proteins (e.g., albumin, retinol binding protein) by cotton fibers has also been described [7] . The goal of the study reported here was to determine whether biomarker concentrations would differ between neonatal urine samples collected indirectly via cotton balls centrifuged prior to storage and those centrifuged prior to analysis. Based on previous studies, we hypothesized that there would be a difference in biomarker concentrations between samples centrifuged prior to storage versus those centrifuged prior to analysis.
Subjects and methods
All hospitalized neonatal intensive care unit (NICU) patients enrolled in the Preterm Erythropoietin Neuroprotection Trial (PENUT; Clinical Trial Number NCT01378273) were eligible for enrollment in this study. PENUT is a multi-center phase III clinical study evaluating the effect of recombinant erythropoietin treatment on the combined outcome of death or severe neurodevelopmental impairment in prematurely born neonates [8] . Urine was collected at the time of study enrollment, per existing protocol, using Fisher brand (Fisher Scientific International, Inc., Pittsburgh, PA) non-sterile large cotton balls placed in the diapers. A prospectively identified cohort of infants was included in this study based on availability of urine for paired biomarker analysis. Informed consent was obtained as part of the PENUT study, and all study procedures were performed in accordance with ethical standards of the local Institutional Review Board and Good Clinical Practice guidelines.
Urine samples were divided into two equal aliquots. The study design is shown in Fig. 1 . One urine aliquot (before storage) was centrifuged at 4000 g at 4°C for 10 min, followed by immediate storage at −80°C. The second aliquot (before analysis) was stored at −80°C without centrifugation, and centrifuged as above at the time of thaw just prior to analysis. Urine samples were stored between 1 and 4 months prior to batch analysis.
Urinary biomarker analysis was performed by electrochemiluminescence on multiarray plates using the Sector Image 2400 microplate detection platform 3 Kit Assay. Albumin, β-2-microglobulin (β2M), cystatin C, epithelial growth factor (EGF), neutrophil gelatinaseassociated lipocalin (NGAL), osteopontin (OPN), and uromodulin (UMOD) were measured in urine using the MSD Human Kidney Injury Panel 5 Kit Assay. Before plating, samples for panel 3 were diluted tenfold and samples for panel 5 were diluted 500-fold. Samples were added to plates and prepared as stated in the manufacturer's protocols and analyzed using standard methodology and manufacturer-reported interassay coefficients of variation (CV) for low, medium, and high concentration analytes [9, 10] . Urine creatinine levels were used to normalize biomarker concentration for urine dilution per standard protocol. However, as the paired aliquots were from the same urine sample, there was no need to normalize for creatinine level for comparisons. All samples were assessed in duplicate on the same plates under similar conditions. Data analysis was performed using R version 3.3.1 [11] . Missing data were excluded rather than imputed as it was not clear if samples were above or below the limits of the standardized curve. The paired t test was utilized to more accurately account for inter-sample differences and was computed for each biomarker. A standard curve was generated using a four parameter logistic model, and used to estimate concentrations for urine samples; p values were adjusted for 13 simultaneous comparisons using the Hochberg method [12] . Mean percentage error was calculated as:
100 Â spun before analysis−spun before storage ½ = spun before analysis þ spun before storage 2 and total percentage error was calculated as the absolute mean percentage error + 2 standard deviations, to calculate error for a continuous variable without bounds. Percentage error and total percentage error were used instead of regression analysis to evaluate for agreement between the two methods for the same clinical measurement [13] . Bland-Altman plots were used to display the mean difference between paired samples with centrifugation prior to storage versus centrifugation prior to analysis [14, 15] .
Results
The median age of patients was 28 (range 3-72) days, and the majority were female (74%). Median gestational age was 26 weeks and 6 days (range 24 weeks and 1 day to 28 weeks and 0 days), and median birth weight was 773 (range 494-1010) g. Urine biomarkers in our paired samples with centrifugation prior to storage versus centrifugation prior to analysis were closely correlated, with the paired t statistics for parameter αGST, α Glutathione S-transferase; KIM-1, kidney injury molecule-1, TFF3, trefoil factor 3; VEGF, vascular epithelial growth factor; β2M, β-2-microglobulin; EGF epithelial growth factor; NGAL, neutrophil gelatinaseassociated lipocalin; OPN, osteopontin; UMOD, uromodulin estimates presented in Table 1 . Positive estimates indicate that biomarker concentration was on average higher in the samples spun before storage, and negative estimates indicate that the concentration was on average higher in the samples spun before analysis. There was excellent concordance between the groups, with no differences in concentration for any of these biomarkers when the samples processed before storage were compared to samples processed before analysis (Fig. 2) .
In addition, the concentration difference between paired samples processed prior to storage versus those processed prior to analysis was within 2% in 12 of the 14 biomarkers (86%) and within 4% in all biomarkers ( Table 2 ). The largest mean percentage error was found for β2M (−3.7%), and the smallest percentage difference was found for EGF (−0.61%). The most common clinically utilized biomarkers demonstrated excellence concordance as well, with mean percentage Abbreviations for urine markers are defined in the footnote to Table 1 errors between paired samples of 1.5% for NGAL, −1.0% for KIM-1, and −0.95% for OPN. The MSD documentation for these immunoassays indicates that the expected intra-plate CV is between 2.5 and 12%, depending on the concentration of the analyte. Therefore, we would expect the standard deviation to be 5-6% of the mean, and two standard deviations to be approximately 10-12% of the mean. The mean percentage error and total percentage error analysis for all biomarkers are presented in Table 2 ; mean percentage error did not show a difference between paired samples processed by centrifugation prior to storage versus prior to analysis, as these values were all smaller than the CV values (Table 2) . Bland-Altman plots demonstrated symmetric clustering around the horizontal line at zero, suggesting minimal difference between paired samples with centrifugation prior to storage vs. centrifugation prior to analysis (Fig. 2) .
Discussion
In this small neonatal cohort, the timing of centrifuging samples in relation to storage did not result in a difference in urinary biomarker values for each of the 14 biomarkers assessed. All biomarker concentration values were within 4%, which is well within the accepted error range of the laboratory measurement itself [9, 10] . This study suggests that performing centrifugation prior to storage of urine samples from neonates is not necessary when neonatal urine samples are collected with Fisher brand non-sterile large cotton balls placed in diapers, thereby simplifying the process of specimen collection, processing, and storage for urinary biomarker analysis. These findings could streamline the collection process of samples in both clinical care and research studies, likely saving time and money and enhancing feasibility, as processing could occur at the time of analysis.
Percentage error and total percentage error analyses assess for inherent biases of the processing as well as whether the expected differences between the two processing methods represent a clinically relevant difference. This measured error is a combination of the true difference between the analyte concentration in the paired samples as well as the variability of the immunoassay. Based on these standards, the observed difference between the paired samples is within the acceptable error for biomarker assays based on both previous studies and published manufacturer guidelines [3, 9, 10] . While total percentage error values are large, it is entirely possible that the differences are solely the expected random variability of an immunoassay instead of true differences due to processing methodology. Additionally, these differences are no larger than would be expected for repeated biomarker sampling of the same urine sample [9, 10] . Therefore, the results for each of the sample pairs do not demonstrate a difference between centrifugation prior to storage versus centrifugation prior to analysis outside the variability in the accuracy of the immunoassay.
Previous studies have provided insights into the effects of various processing and storage conditions on biomarker stability, investigating such factors as centrifugation, protease inhibitors, and temperature [16] . To date, these studies have been in adults or children, with urine collected directly by catheterization. Parikh et al. investigated methods of processing samples for biomarker analysis in adult patients and found that with urine samples collected by catheterization, immediate storage without centrifugation did not influence biomarker results [5] . The present study utilized similar methodology and demonstrated that this is also true in neonates with urine collected indirectly via cotton balls. Previous investigations show comparable total protein values in spontaneously voided urine compared to urine collected indirectly via diapers; however, these studies did note a 10% reduction in total protein values in samples [17] . Concerns about the impact of cotton fibers have long been noted in neonatal research protocols with urinary biomarker analysis, but the results of our study suggest that this processing step prior to storage is not necessary [4] .
While we did not assess differences in biomarker stability based on short-term storage conditions, recent work by other groups have examined various storage techniques on the stability of urinary biomarkers. Schuh et al. assessed the impact of storage conditions on biomarker stability in pediatric cardiac surgery patients, finding that short-term storage for up to 24 h at 4°C did not impact biomarker results and that biomarker concentrations were stable at −80°C for up to 5 years [6] . Based on the findings of our study, along with those of these other recent works, it appears that neonatal urine samples for biomarker analysis can be collected and stored without centrifugation and processed at the time of biomarker analysis without any impact on biomarker concentrations for at least up to 5 years. This study does have several limitations. First, we utilized a small convenience sample of infants with urine samples already collected as part of an ongoing research study. Additionally, while a paired analysis is the most powerful test for detecting differences between samples processed with different techniques, there may not have been enough samples to show small but consistent differences. Thirdly, with our study design, we could not assess absorption of proteins by the cotton prior to centrifugation, which would result in absolute values that were systemically less than those seen with direct catheterization. To test this possibility, we would have required a different methodology, including direct urine collection (e.g., bladder catheterization).
In summary, we suggest that centrifugation of urine samples in neonates as part of processing prior to sample storage is not required. Given the difficulties in obtaining adequate urine samples in this patient group, researchers and clinicians frequently utilize disposable diapers with cotton balls placed in the diapers to obtain urine specimens for analysis. Based on the results of our study, urine samples can be processed and then centrifuged just prior to analysis to assess qualitative and quantitative urinary biomarker expression when using Fisher brand non-sterile large cotton balls placed in diapers. The ability to use this routine urine collection method to obtain samples for subsequent quantitative immunoassay analysis should greatly facilitate the use of these techniques in studies of newborns and young children.
